Holen Sie sich die Stockscreener-App
24.62
5.71%
-1.49
Handel nachbörslich:
24.64
0.02
+0.08%
Schlusskurs vom Vortag:
$26.11
Offen:
$26.11
24-Stunden-Volumen:
51,792
Relative Volume:
1.88
Marktkapitalisierung:
$230.47M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-13.61%
1M Leistung:
-7.23%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$24.62
$26.85
1-Wochen-Bereich:
$24.62
$29.45
52-Wochen-Spanne:
$15.80
$34.31
Tvardi Therapeutics Inc Stock (TVRD) Company Profile
Firmenname
Tvardi Therapeutics Inc
Sektor
Branche
Telefon
(713) 489-8654
Adresse
3 SUGAR CREEK CTR. BLVD., SUGAR LAND
Vergleichen Sie TVRD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TVRD
Tvardi Therapeutics Inc
|
24.62 | 230.47M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Tvardi Therapeutics Inc Stock (TVRD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-12 | Eingeleitet | Piper Sandler | Overweight |
| 2025-05-21 | Eingeleitet | Oppenheimer | Outperform |
| 2025-05-15 | Eingeleitet | BTIG Research | Buy |
| 2024-06-13 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2024-06-13 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-06-13 | Herabstufung | Needham | Buy → Hold |
| 2024-06-13 | Herabstufung | Stifel | Buy → Hold |
| 2023-03-08 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-03-08 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-11-01 | Fortgesetzt | Canaccord Genuity | Buy |
| 2021-08-03 | Eingeleitet | JP Morgan | Neutral |
| 2020-04-21 | Bestätigt | H.C. Wainwright | Buy |
| 2019-08-12 | Bestätigt | H.C. Wainwright | Buy |
| 2019-05-29 | Bestätigt | Laidlaw | Buy |
| 2019-02-06 | Fortgesetzt | Jefferies | Buy |
| 2019-01-15 | Eingeleitet | BofA/Merrill | Neutral |
| 2018-09-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-13 | Eingeleitet | Jefferies | Buy |
| 2018-08-08 | Bestätigt | Stifel | Buy |
| 2018-06-28 | Bestätigt | H.C. Wainwright | Buy |
| 2018-03-12 | Fortgesetzt | H.C. Wainwright | Buy |
| 2018-02-12 | Hochstufung | Janney | Neutral → Buy |
| 2018-01-19 | Eingeleitet | Seaport Global Securities | Buy |
Alle ansehen
Tvardi Therapeutics Inc Aktie (TVRD) Neueste Nachrichten
Recently Listed Tvardi Therapeutics' Lead Drug 'Positioned To Drive Broad Improvement', Analyst Sees Over 150% Stock Upside - Benzinga
Piper Sandler Initiates Coverage on Tvardi Therapeutics With Overweight Rating - marketscreener.com
Piper Sandler initiates Tvardi Therapeutics stock with overweight rating - Investing.com Australia
Piper Sandler initiates Tvardi Therapeutics stock with overweight rating By Investing.com - Investing.com India
Tvardi Therapeutics Updates Corporate Presentation on Therapies - TipRanks
BTIG maintains $55 target on Tvardi stock, reiterates buy By Investing.com - Investing.com South Africa
BTIG maintains $55 target on Tvardi stock, reiterates buy - Investing.com
Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of Tti-101 in Idiopathic Pulmonary Fibrosis - marketscreener.com
Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis - marketscreener.com
Tvardi Completes Enrollment for Phase 2 IPF Trial - TipRanks
TVRD Stock Hits 52-Week High at $29.22 Amid Market Optimism By Investing.com - Investing.com South Africa
TVRD Stock Hits 52-Week High at $29.22 Amid Market Optimism - Investing.com
Oppenheimer Initiates Tvardi Therapeutics at Outperform With $65 Price Target - marketscreener.com
Oppenheimer sets $65 target on Tvardi stock with Outperform rating - Investing.com
Oppenheimer sets $65 target on Tvardi stock with Outperform rating By Investing.com - Investing.com India
Tvardi Therapeutics to Participate in Upcoming Investor Conferences - FinancialContent
BTIG Initiates Tvardi Therapeutics at Buy With $55 Price Target - marketscreener.com
BTIG sets $55 target on Tvardi Therapeutics stock with Buy rating - Investing.com
Cara Therapeutics Stock Jumps 10% After Announcing 1-for-3 Reverse Stock Split: Retail Sentiment Soars - MSN
Tvardi maps out path to Phase II data after Cara merger - The Pharma Letter
Tvardi: Q1 Earnings Snapshot - Huron Daily Tribune
Tvardi Therapeutics Announces First Quarter 2025 Results and Provides Business Update - Business Wire
Tvardi Therapeutics Inc expected to post a loss of 35 cents a shareEarnings Preview - TradingView
Tvardi Therapeutics Announces Presentation at the American Thoracic Society 2025 Annual Conference - Business Wire
Lucid Capital Markets sets $42 target for Tvardi Therapeutics stock By Investing.com - Investing.com Canada
Lucid Capital Markets sets $42 target for Tvardi Therapeutics stock - Investing.com
Form 8-KCurrent report - ADVFN
TVRD stock soars to 52-week high, reaching $19.01 - Investing.com Australia
Tvardi Therapeutics, Inc. Rings the Closing Bell - Nasdaq
TVRD Stock Price and Chart — NASDAQ:TVRD - TradingView
Tvardi Therapeutics, Inc. Rings the Nasdaq Stock Market Closing Bell - Nasdaq
Tvardi Therapeutics Closes Merger with Cara Therapeutics - citybiz
Cara Therapeutics Completes Merger with Tvardi Therapeutics - TipRanks
Tvardi Therapeutics Announces Closing of Merger with Cara Therapeutics - GlobeNewswire
Cara Therapeutics announces 1-for-3 reverse stock split related to Tvardi merger - Hartford Business Journal
Cara Therapeutics (CARA) to Rebrand and Trade as Tvardi Therapeu - GuruFocus
Cara Therapeutics Announces 1-for-3 Reverse Stock Split - citybiz
Cara Therapeutics Announces 1-For-3 Reverse Stock Split - marketscreener.com
Cara Approves Reverse Split in Connection With Tvardi Merger - marketscreener.com
Cara Therapeutics Announces 1-for-3 Reverse Stock Split in Connection with the Proposed Merger with Tvardi Therapeutics | CARA Stock News - GuruFocus
Cara Therapeutics announces 1-for-3 reverse stock split By Investing.com - Investing.com UK
Cara Therapeutics Announces 1-for-3 Reverse Stock Split in - GlobeNewswire
Major Transformation: Cara Therapeutics Unveils 1:3 Split Plan Before Tvardi Merger - Stock Titan
Cara Therapeutics Announces 1-for-3 Reverse Stock Split in Conne - GuruFocus
Cara Therapeutics CEO Posner sells shares worth $1,755 - MSN
Cara Therapeutics Announces Merger with Tvardi Therapeutics - TipRanks
Cara Therapeutics approves merger and stock plans By Investing.com - Investing.com India
Cara Therapeutics approves merger and stock plans - Investing.com
Finanzdaten der Tvardi Therapeutics Inc-Aktie (TVRD)
Es liegen keine Finanzdaten für Tvardi Therapeutics Inc (TVRD) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
1.91%
1.17%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):